What is Emergent Biosolutions, Inc.'s earnings per share (EPS)?

Emergent Biosolutions, Inc. (EBS) reported diluted earnings per share of $0.93 for fiscal year 2025. This represents a 125.8% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Emergent Biosolutions, Inc. (EBS) Financials

EBS

Trailing 12 months to June 30, 2026

Revenue $770.2M -9.6% YoY

Net Income -$176.8M -226.7% YoY

EPS (Diluted) -$3.47 -241.1% YoY

Free Cash Flow $85.9M -44.6% YoY

Market Cap $362.0M as of Oct 10, 2026

Price / Sales 0.5x on $770.2M revenue, trailing 12 months to June 30, 2026

Price / Earnings n/m net loss, so no earnings multiple, trailing 12 months to June 30, 2026

Price / Book 1.1x on $341.4M equity, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 10, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 6, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Aug 6, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the EBS SEC filings page.

Emergent Biosolutions, Inc. (EBS) reported $770.2M in revenue over the twelve months to Jun 30, 2026, down 9.6% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI EBS FY2025 2026-10-03

Emergent returned to profitability with smaller revenue, but sharply better margins and cash conversion now drive the business.

FY2025 revenue fell to $743M, yet gross margin reached 56.1%; profitability therefore improved without volume growth, pointing to a changed cost or revenue mix rather than scale alone. That interpretation fits SG&A falling to $186M while operating income turned positive, showing the earnings recovery was tied to a leaner expense base.

Cash conversion was favorable in FY2025: operating cash flow was $171M against net income of $53M, so reported earnings translated into more cash than accrual profit alone. Free cash flow reached $157M while capital spending was just $14M, indicating cash generation did not require heavy reinvestment that year.

Short-term coverage reached 5.0x, while debt-to-equity was 1.1x; this is better liquidity alongside continued reliance on debt financing. Total liabilities fell to $796M while equity rose to $523M, so the balance-sheet improvement came from both lower obligations and a rebuilt equity base.

Financial Health Signals

Financial Health Score 36/100

Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Emergent Biosolutions, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability

Emergent Biosolutions, Inc. has an operating margin of 13.5%, meaning the company retains $13 of operating profit per $100 of revenue. This below-average margin results in a low score of 16/100, suggesting thin profitability after operating expenses. This is up from -10.4% the prior year.

Growth

Emergent Biosolutions, Inc.'s revenue declined 28.8% year-over-year, from $1.0B to $742.9M. This contraction results in a growth score of 5/100.

Leverage

Emergent Biosolutions, Inc. has a moderate D/E ratio of 1.09. This balance of debt and equity financing earns a leverage score of 33/100.

Liquidity

With a current ratio of 5.01, Emergent Biosolutions, Inc. holds $5.01 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 92/100.

Cash Flow

Emergent Biosolutions, Inc. has a free cash flow margin of 21.1%, earning a moderate score of 53/100. The company generates positive cash flow after capital investments, but with room for improvement.

Returns

Emergent Biosolutions, Inc. generates a 10.1% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 17/100. This is up from -39.5% the prior year.

Altman Z-Score Distress

1.40

Emergent Biosolutions, Inc. scores 1.40, below the 1.81 distress threshold. This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Strong

8/9

Emergent Biosolutions, Inc. passes 8 of 9 financial strength tests. All 4 profitability signals pass (positive income, cash flow, and earnings quality), all 3 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.

Earnings Quality Cash-Backed

3.24x

For every $1 of reported earnings, Emergent Biosolutions, Inc. generates $3.24 in operating cash flow ($170.6M OCF vs $52.6M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.

Interest Coverage At Risk

1.69x

Emergent Biosolutions, Inc. earns $1.69 in operating income for every $1 of interest expense ($100.1M vs $59.3M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$234.3M

YoY+66.3%

QoQ+50.1%

5Y CAGR-9.1%

10Y CAGR+9.9%

Emergent Biosolutions, Inc. generated $234.3M in revenue in Q2 2026. This represents an increase of 66.3% from the same quarter a year earlier. Against the prior quarter it is up 50.1%.

EBITDA

-$101.1M

YoY-502.8%

QoQ-397.4%

Emergent Biosolutions, Inc.'s EBITDA was -$101.1M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 502.8% from the same quarter a year earlier. Against the prior quarter it is down 397.4%.

Net Income

-$180.2M

YoY-1401.7%

QoQ-2750.0%

Emergent Biosolutions, Inc. reported -$180.2M in net income in Q2 2026. This represents a decrease of 1401.7% from the same quarter a year earlier. Against the prior quarter it is down 2750.0%.

EPS (Diluted)

-$3.49

YoY-1486.4%

Emergent Biosolutions, Inc. earned -$3.49 per diluted share (EPS) in Q2 2026. This represents a decrease of 1486.4% from the same quarter a year earlier.

Cash & Balance Sheet

Free Cash Flow

$54.0M

YoY-47.8%

QoQ+249.2%

Emergent Biosolutions, Inc. generated $54.0M in free cash flow in Q2 2026, representing cash available after capex. This represents a decrease of 47.8% from the same quarter a year earlier. Against the prior quarter it is up 249.2%.

Cash & Debt

$139.7M

YoY-47.7%

QoQ-12.9%

5Y CAGR-20.8%

10Y CAGR-8.3%

Emergent Biosolutions, Inc. held $139.7M in cash against $581.8M in long-term debt as of Q2 2026.

Shares Outstanding

51M

YoY-3.9%

5Y CAGR-0.9%

10Y CAGR+2.4%

Emergent Biosolutions, Inc. had 51M shares outstanding in Q2 2026. This represents a decrease of 3.9% from the same quarter a year earlier.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Gross Margin

58.6%

YoY+6.0pp

QoQ+4.7pp

Emergent Biosolutions, Inc.'s gross margin was 58.6% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is up 6.0 percentage points from the same quarter a year earlier. Against the prior quarter it is up 4.7 percentage points.

Operating Margin

-53.4%

YoY-54.5pp

QoQ-60.1pp

5Y change-55.3pp

Emergent Biosolutions, Inc.'s operating margin was -53.4% in Q2 2026, reflecting core business profitability. This is down 54.5 percentage points from the same quarter a year earlier. Against the prior quarter it is down 60.1 percentage points.

Net Margin

-76.9%

YoY-68.4pp

QoQ-81.3pp

5Y change-76.8pp

Emergent Biosolutions, Inc.'s net profit margin was -76.9% in Q2 2026, showing the share of revenue converted to profit. This is down 68.4 percentage points from the same quarter a year earlier. Against the prior quarter it is down 81.3 percentage points.

Return on Equity

-52.8%

YoY-50.5pp

QoQ-54.1pp

5Y change-52.8pp

Emergent Biosolutions, Inc.'s ROE was -52.8% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is down 50.5 percentage points from the same quarter a year earlier. Against the prior quarter it is down 54.1 percentage points.

Capital Allocation

R&D Spending

$9.2M

YoY-26.4%

QoQ-12.4%

Emergent Biosolutions, Inc. invested $9.2M in research and development in Q2 2026. This represents a decrease of 26.4% from the same quarter a year earlier. Against the prior quarter it is down 12.4%.

Share Buybacks

$9.0M

YoY+30.4%

QoQ0.0%

Emergent Biosolutions, Inc. spent $9.0M on share buybacks in Q2 2026, returning capital to shareholders by reducing shares outstanding. This represents an increase of 30.4% from the same quarter a year earlier. It is unchanged from the prior quarter.

Capital Expenditures

$2.1M

YoY-27.6%

QoQ-12.5%

5Y CAGR-50.0%

10Y CAGR-20.6%

Emergent Biosolutions, Inc. invested $2.1M in capex in Q2 2026, funding long-term assets and infrastructure. This represents a decrease of 27.6% from the same quarter a year earlier. Against the prior quarter it is down 12.5%.

EBS Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

EBS quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Revenue	$770.2M	$742.9M-28.8%	$1.0B-0.5%	$1.0B-6.1%	$1.1B-37.0%	$1.8B+12.4%	$1.6B+42.6%	$1.1B+41.4%	$782.4M+39.5%	$560.9M+14.8%	$488.8M-6.5%	$522.8M+16.1%	$450.1M+43.9%	$312.7M+10.9%	$281.9M+3.1%	$273.4M
Cost of Revenue	$339.9M	$326.2M-52.1%	$681.3M-3.4%	$705.4M+1.8%	$693.1M-7.4%	$748.1M+39.3%	$537.0M+23.9%	$433.5M+34.5%	$322.3M+71.7%	$187.7M+48.6%	$126.3M+17.5%	$107.5M+5.4%	$102.0M+64.1%	$62.1M+34.8%	$46.1M+9.3%	$42.2M
Gross Profit	$430.3M	$416.7M+15.0%	$362.3M+14.1%	$317.6M-17.1%	$383.0M-57.0%	$891.3M-3.7%	$925.2M+37.6%	$672.5M+46.2%	$460.1M+23.3%	$373.2M+3.0%	$362.5M-12.7%	$415.3M+19.3%	$348.2M+38.9%	$250.6M+6.3%	$235.8M+2.0%	$231.2M
R&D Expenses	$45.3M	$53.2M-24.8%	$70.7M-36.5%	$111.4M-40.8%	$188.3M-19.9%	$235.2M-1.1%	$237.9M+5.2%	$226.2M+58.4%	$142.8M+46.6%	$97.4M-8.9%	$106.9M-10.3%	$119.2M+13.8%	$104.7M-12.7%	$119.9M-0.2%	$120.2M-3.7%	$124.8M
SG&A Expenses	$181.2M	$186.1M-39.6%	$308.0M-16.4%	$368.4M+8.5%	$339.5M-2.6%	$348.7M+14.7%	$304.1M+11.2%	$273.5M+35.1%	$202.5M+41.7%	$142.9M-0.1%	$143.1M+18.1%	$121.1M+11.6%	$108.6M+23.6%	$87.9M+15.6%	$76.0M+2.3%	$74.3M
Operating Income	-$66.0M	$100.1M+192.1%	-$108.7M+85.0%	-$726.4M-327.3%	-$170.0M-149.8%	$341.4M-22.1%	$438.5M+284.3%	$114.1M+27.1%	$89.8M-27.8%	$124.3M+17.8%	$105.5M-25.4%	$141.5M+58.7%	$89.2M+108.4%	$42.8M+42.8%	$30.0M-6.6%	$32.1M
EBITDA	N/A	$195.9M+195800.0%	$100K+100.0%	-$601.3M-2152.1%	-$26.7M-105.7%	$465.2M-4.8%	$488.6M+198.7%	$163.6M+29.7%	$126.1M-19.4%	$156.5M+17.2%	$133.5M-19.2%	$165.3M+48.2%	$111.5M+86.5%	$59.8M+45.3%	$41.2M-0.7%	$41.5M
Interest Expense	$50.9M	$59.3M-16.5%	$71.0M-19.2%	$87.9M+135.7%	$37.3M+8.1%	$34.5M+10.2%	$31.3M-18.5%	$38.4M+287.9%	$9.9M+50.0%	$6.6M-13.2%	$7.6M+16.5%	$6.5M-20.8%	$8.2M	$0-100.0%	$6K	$0
Income Tax	$30.8M	$30.2M-36.7%	$47.7M+62.8%	$29.3M+495.9%	-$7.4M-108.8%	$83.7M-21.1%	$106.1M+363.3%	$22.9M+21.8%	$18.8M-47.8%	$36.0M-1.9%	$36.7M-17.2%	$44.3M+48.0%	$29.9M+128.3%	$13.1M-5.8%	$13.9M-12.1%	$15.8M
Net Income	-$176.8M	$52.6M+127.6%	-$190.6M+74.9%	-$760.5M-259.4%	-$211.6M-196.4%	$219.5M-28.2%	$305.8M+461.1%	$54.5M-13.1%	$62.7M-24.1%	$82.6M+59.5%	$51.8M-17.6%	$62.9M+71.1%	$36.7M+18.0%	$31.1M+32.4%	$23.5M+2.2%	$23.0M
EPS (Basic)	N/A	$0.98+127.2%	-$3.60+75.8%	-$14.85-251.9%	-$4.22-202.9%	$4.10-29.3%	$5.80+447.2%	$1.06-15.2%	$1.25-36.9%	$1.98+53.5%	$1.29-20.9%	$1.63+66.3%	$0.98+14.0%	$0.86+32.3%	$0.650.0%	$0.65
EPS (Diluted)	-$3.47	$0.93+125.8%	-$3.60+75.8%	-$14.85-251.9%	-$4.22-203.9%	$4.06-28.5%	$5.68+446.2%	$1.04-14.8%	$1.22-28.7%	$1.71+51.3%	$1.13-19.9%	$1.41+60.2%	$0.88+3.5%	$0.85+30.8%	$0.65+1.6%	$0.64
Diluted Shares (Avg)	N/A	57M+7.0%	53M+3.5%	51M+2.2%	50M-7.4%	54M+0.6%	54M+2.7%	52M+1.9%	51M+2.2%	50M+2.0%	49M+4.3%	47M+3.2%	46M+24.6%	37M+0.9%	36M+0.6%	36M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Revenue	$234.3M+66.3%	$156.1M-29.7%	$148.7M-23.6%	$231.1M-21.3%	$140.9M-44.7%	$222.2M-26.0%	$194.7M-29.6%	$293.8M+8.6%
Cost of Revenue	$97.1M+45.1%	$72.0M-18.6%	$84.9M-28.1%	$85.9M-29.9%	$66.9M-77.4%	$88.5M-38.8%	$118.0M-36.3%	$122.6M-30.7%
Gross Profit	$137.2M+85.4%	$84.1M-37.1%	$63.8M-37.0%	$145.2M-9.9%	$74.0M+254.2%	$133.7M-9.5%	$101.3M+19.5%	$161.2M+84.9%
R&D Expenses	$9.2M-26.4%	$10.5M-30.5%	$12.1M+33.0%	$13.5M-2.2%	$12.5M-61.8%	$15.1M0.0%	$9.1M-69.0%	$13.8M-9.8%
SG&A Expenses	$44.6M+2.1%	$46.6M-11.1%	$51.1M-16.0%	$38.9M-49.2%	$43.7M-49.1%	$52.4M-38.1%	$60.8M-32.2%	$76.6M-10.9%
Operating Income	-$125.1M-7918.8%	$10.5M-79.0%	-$27.9M-193.7%	$76.5M+18.6%	$1.6M+100.8%	$49.9M+25.4%	-$9.5M+78.3%	$64.5M+126.6%
EBITDA	-$101.1M-502.8%	$34.0M-54.8%	-$4.4M-126.7%	$99.9M+9.9%	$25.1M+114.3%	$75.3M+11.2%	$16.5M+216.2%	$90.9M+142.5%
Interest Expense	$10.0M-32.0%	$11.0M-25.2%	$14.7M-0.7%	$15.2M+83.1%	$14.7M-37.7%	$14.7M-39.5%	$14.8M-31.8%	$8.3M-57.9%
Income Tax	$13.9M+389.6%	$6.6M-73.3%	$3.9M+5.4%	$6.4M-76.8%	-$4.8M-136.1%	$24.7M+696.8%	$3.7M+174.0%	$27.6M+1204.0%
Net Income	-$180.2M-1401.7%	$6.8M-90.0%	-$54.6M-74.4%	$51.2M-55.4%	-$12.0M+95.8%	$68.0M+655.6%	-$31.3M+36.8%	$114.8M+143.6%
EPS (Basic)	-$3.49-1486.4%	$0.13-89.6%	-$1.01-77.2%	$0.96-55.6%	-$0.22+95.9%	$1.25+635.3%	-$0.57+35.2%	$2.16+142.5%
EPS (Diluted)	-$3.49-1486.4%	$0.07	-$0.96-68.4%	$0.91-55.8%	-$0.22+95.9%	$1.19+600.0%	-$0.57+35.2%	$2.06+140.6%
Diluted Shares (Avg)	52M-4.8%	57M	N/A	57M+1.6%	54M+3.0%	57M+9.8%	N/A	56M+7.3%

EBS Balance Sheet

EBS quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Total Assets	$1.3B-5.1%	$1.4B-23.8%	$1.8B-42.4%	$3.2B+7.1%	$3.0B+2.6%	$2.9B+23.9%	$2.3B+4.4%	$2.2B+108.3%	$1.1B+10.3%	$970.1M-6.5%	$1.0B+10.5%	$938.7M+49.8%	$626.6M+11.1%	$564.2M+3.2%	$546.9M
Current Assets	$662.5M+10.7%	$598.7M-11.9%	$679.5M-43.9%	$1.2B-4.7%	$1.3B+6.2%	$1.2B+74.3%	$686.2M+10.5%	$620.8M+27.9%	$485.4M-4.9%	$510.2M-5.1%	$537.4M+24.4%	$432.2M+58.2%	$273.1M+3.7%	$263.3M+3.5%	$254.4M
Cash & Equivalents	$205.4M+106.4%	$99.5M-10.9%	$111.7M-82.6%	$642.6M+11.5%	$576.1M-7.3%	$621.3M+270.3%	$167.8M+49.6%	$112.2M-37.1%	$178.3M-34.3%	$271.5M-13.2%	$312.8M+11.5%	$280.5M+56.4%	$179.3M+26.6%	$141.7M-1.6%	$143.9M
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0-100.0%	$2.0M
Inventory	$343.4M+10.2%	$311.7M-5.2%	$328.9M-6.2%	$350.7M+1.8%	$344.5M+12.2%	$307.0M+38.0%	$222.5M+8.1%	$205.8M+44.1%	$142.8M+93.0%	$74.0M+21.5%	$60.9M-7.3%	$65.7M+348.5%	$14.6M-3.4%	$15.2M+3.4%	$14.7M
Accounts Receivable	$84.2M-45.5%	$154.5M-19.1%	$191.0M+20.0%	$159.2M-42.9%	$278.9M+20.8%	$230.9M-14.7%	$270.7M+3.1%	$262.5M+82.7%	$143.7M+3.8%	$138.5M+21.6%	$113.9M+93.6%	$58.8M-2.9%	$60.6M-36.9%	$96.0M+29.5%	$74.2M
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Goodwill	$0	$0	$0-100.0%	$218.2M-3.0%	$224.9M-15.7%	$266.7M0.0%	$266.6M+2.7%	$259.7M+428.9%	$49.1M+19.8%	$41.0M0.0%	$41.0M-22.0%	$52.6M+276.8%	$14.0M+153.6%	$5.5M0.0%	$5.5M
Total Liabilities	$796.0M-12.2%	$906.9M-22.7%	$1.2B-34.0%	$1.8B+32.1%	$1.3B-6.3%	$1.4B+15.9%	$1.2B+1.7%	$1.2B+671.7%	$157.9M-57.8%	$373.9M-0.9%	$377.5M-2.1%	$385.5M+180.4%	$137.5M+12.6%	$122.1M-6.2%	$130.1M
Current Liabilities	$132.2M-18.6%	$162.4M-75.1%	$651.3M-47.0%	$1.2B+228.6%	$374.0M-2.7%	$384.5M+77.8%	$216.3M+7.9%	$200.4M+100.2%	$100.1M-5.4%	$105.9M+6.3%	$99.6M+7.2%	$92.9M+64.1%	$56.7M-8.5%	$61.9M-12.9%	$71.1M
Non-Current Liabilities	$663.8M-10.8%	$744.5M+42.5%	$522.6M-4.9%	$549.7M-43.5%	$972.2M-7.6%	$1.1B+2.9%	$1.0B+0.4%	$1.0B+1661.4%	$57.8M-78.4%	$268.1M-3.5%	$277.9M-5.0%	$292.6M+262.0%	$80.8M+34.3%	$60.2M+1.9%	$59.1M
Long-Term Debt	$572.1M-13.8%	$663.7M+48.6%	$446.5M-0.4%	$448.5M-44.6%	$809.4M-3.8%	$841.0M+5.3%	$798.4M+1.8%	$784.5M+5711.1%	$13.5M-94.6%	$248.1M+0.5%	$246.9M-1.6%	$251.0M+304.8%	$62.0M+6.3%	$58.3M+7.8%	$54.1M
Total Equity	$522.6M+8.2%	$482.8M-25.6%	$649.3M-53.2%	$1.4B-13.9%	$1.6B+11.1%	$1.5B+33.0%	$1.1B+8.0%	$1.0B+10.8%	$912.3M+53.0%	$596.2M-9.7%	$660.0M+19.3%	$553.2M+13.0%	$489.6M+10.9%	$441.4M+6.5%	$414.2M
Retained Earnings	-$159.8M+24.8%	-$212.4M-874.3%	-$21.8M-103.0%	$738.7M-22.3%	$950.3M+30.7%	$726.9M+72.3%	$421.8M+14.8%	$367.3M+9.0%	$337.1M+32.5%	$254.5M-27.5%	$351.1M+21.8%	$288.3M+14.6%	$251.5M+14.1%	$220.4M+11.9%	$196.9M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$1.1B-21.2%	$1.3B-7.4%	$1.3B-5.1%	$1.5B-1.1%	$1.4B-6.4%	$1.4B-20.9%	$1.4B-23.8%	$1.5B-21.9%
Current Assets	$666.0M-7.4%	$637.6M-9.8%	$662.5M+10.7%	$786.9M+19.0%	$719.5M+9.9%	$706.8M+3.6%	$598.7M-11.9%	$661.4M-8.2%
Cash & Equivalents	$139.7M-47.7%	$160.3M+7.5%	$205.4M+106.4%	$245.5M+63.8%	$267.3M+283.5%	$149.1M+89.9%	$99.5M-10.9%	$149.9M+70.7%
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Inventory	$303.6M-10.3%	$327.6M+4.3%	$343.4M+10.2%	$356.3M+10.4%	$338.6M+6.6%	$314.0M-5.8%	$311.7M-5.2%	$322.7M-8.9%
Accounts Receivable	$190.0M+138.1%	$121.6M-40.3%	$84.2M-45.5%	$149.5M+23.2%	$79.8M-59.3%	$203.7M-12.8%	$154.5M-19.1%	$121.3M-44.0%
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Goodwill	N/A	N/A	$0	N/A	N/A	N/A	$0	$0
Total Liabilities	$775.4M-12.0%	$797.3M-8.7%	$796.0M-12.2%	$878.5M-9.4%	$880.9M-21.9%	$873.4M-23.4%	$906.9M-22.7%	$969.4M-18.9%
Current Liabilities	$122.8M-3.4%	$148.7M+32.9%	$132.2M-18.6%	$136.5M-40.6%	$127.1M-79.5%	$111.9M-82.2%	$162.4M-75.1%	$229.9M-65.4%
Non-Current Liabilities	$652.6M-13.4%	$648.6M-14.8%	$663.8M-10.8%	$742.0M+0.3%	$753.8M+48.5%	$761.5M+49.5%	$744.5M+42.5%	$739.5M+39.0%
Long-Term Debt	$581.8M-12.9%	$573.6M-13.8%	$572.1M-13.8%	$663.1M+0.2%	$667.8M+49.4%	$665.7M+49.0%	$663.7M+48.6%	$661.8M+47.7%
Total Equity	$341.4M-36.3%	$523.1M-5.4%	$522.6M+8.2%	$582.5M+14.6%	$536.2M+38.8%	$552.7M-16.7%	$482.8M-25.6%	$508.4M-27.1%
Retained Earnings	-$333.2M-113.0%	-$153.0M-6.0%	-$159.8M+24.8%	-$105.2M+41.9%	-$156.4M+47.1%	-$144.4M-1028.1%	-$212.4M-874.3%	-$181.1M-753.8%

EBS Cash Flow Statement

EBS quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Operating Cash Flow	$97.7M	$170.6M+190.6%	$58.7M+128.5%	-$206.3M-505.0%	-$34.1M-110.6%	$320.2M-40.4%	$536.9M+185.6%	$188.0M+349.8%	$41.8M-79.9%	$208.1M+281.1%	$54.6M+28.4%	$42.5M-62.1%	$112.3M+15.8%	$97.0M+144.6%	$39.6M+225.3%	$12.2M
Depreciation & Amortization	N/A	$95.8M-11.9%	$108.8M-13.0%	$125.1M-12.7%	$143.3M+15.8%	$123.8M+147.1%	$50.1M+1.2%	$49.5M+36.4%	$36.3M+12.7%	$32.2M+14.9%	$28.0M+18.1%	$23.7M+6.3%	$22.3M+31.3%	$17.0M+51.9%	$11.2M+19.7%	$9.4M
Stock-Based Compensation	N/A	$16.2M-10.0%	$18.0M-22.1%	$23.1M-48.8%	$45.1M+6.4%	$42.4M-18.1%	$51.8M+94.0%	$26.7M+15.1%	$23.2M+52.6%	$15.2M-17.8%	$18.5M+16.7%	$15.8M+23.5%	$12.8M+14.2%	$11.2M+1.1%	$11.1M+3.5%	$10.7M
Capital Expenditures	$11.8M	$13.8M-39.7%	$22.9M-55.6%	$51.6M-55.4%	$115.8M-48.3%	$224.1M+57.9%	$141.9M+63.3%	$86.9M+20.5%	$72.1M+31.6%	$54.8M-28.1%	$76.2M+70.0%	$44.8M+46.1%	$30.7M-27.0%	$42.0M-22.0%	$53.8M-0.3%	$54.0M
Free Cash Flow	$85.9M	$156.8M+338.0%	$35.8M+113.9%	-$257.9M-72.0%	-$149.9M-256.0%	$96.1M-75.7%	$395.0M+290.7%	$101.1M+433.7%	-$30.3M-119.8%	$153.3M+809.7%	-$21.6M-841.2%	-$2.3M-102.8%	$81.6M+48.6%	$54.9M+486.9%	-$14.2M+66.1%	-$41.8M
Investing Cash Flow	-$62.0M	$69.4M-44.6%	$125.2M-41.0%	$212.3M+155.7%	-$381.3M-70.1%	-$224.1M-47.5%	-$151.9M-56.8%	-$96.9M+89.2%	-$897.2M-259.0%	-$249.9M-228.0%	-$76.2M-67.6%	-$45.5M+78.4%	-$210.1M-209.4%	-$67.9M-69.3%	-$40.1M+25.7%	-$54.0M
Financing Cash Flow	-$165.6M	-$136.6M+28.1%	-$190.0M+64.5%	-$535.7M-211.3%	$481.2M+441.3%	-$141.0M-302.9%	$69.5M+293.6%	-$35.9M-104.6%	$788.7M+1634.4%	-$51.4M-159.6%	-$19.8M-155.9%	$35.4M-82.2%	$198.9M+2209.3%	$8.6M+587.9%	-$1.8M-110.6%	$16.7M
Share Buybacks	$36.0M	$24.9M	$0	$0-100.0%	$82.1M-22.5%	$106.0M	$0	$0-100.0%	$100K-99.7%	$33.1M	$0-100.0%	$100K-50.0%	$200K-6.1%	$213K-96.4%	$5.9M	$0

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	$56.1M-47.3%	-$33.8M-201.8%	$77.7M+197.2%	-$2.3M-101.5%	$106.4M+124.0%	-$11.2M+82.1%	-$79.9M-348.9%	$153.7M+156.2%
Depreciation & Amortization	$24.0M+2.1%	$23.5M-7.5%	$23.5M-9.6%	$23.4M-11.4%	$23.5M-17.5%	$25.4M-9.0%	$26.0M-12.2%	$26.4M-5.7%
Stock-Based Compensation	$6.9M+50.0%	$1.9M+26.7%	N/A	$4.8M+108.7%	$4.6M-16.4%	$1.5M-74.6%	N/A	$2.3M-42.5%
Capital Expenditures	$2.1M-27.6%	$2.4M-33.3%	$3.9M+129.4%	$3.4M-41.4%	$2.9M-37.0%	$3.6M-66.7%	$1.7M-85.1%	$5.8M-54.0%
Free Cash Flow	$54.0M-47.8%	-$36.2M-144.6%	$73.8M+190.4%	-$5.7M-103.9%	$103.5M+141.3%	-$14.8M+79.8%	-$81.6M-494.2%	$147.9M+212.0%
Investing Cash Flow	-$52.3M-404.1%	-$2.4M-104.0%	-$3.9M-113.6%	-$3.4M-103.0%	$17.2M+473.9%	$59.5M+650.9%	$28.6M+350.9%	$112.0M+692.6%
Financing Cash Flow	-$24.4M-281.3%	-$11.4M-2750.0%	-$113.9M-22880.0%	-$15.9M+91.2%	-$6.4M+87.4%	-$400K-101.0%	$500K-89.4%	-$180.3M-319.3%
Share Buybacks	$9.0M+30.4%	$9.0M	$9.1M	$8.9M	$6.9M	$0	$0	$0

Not reported in any period shown, so not listed: Dividends Paid.

EBS Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

EBS quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Gross Margin	56.1%+21.4pp	34.7%+4.4pp	30.3%-4.0pp	34.3%-16.0pp	50.2%-8.4pp	58.7%-2.1pp	60.8%+2.0pp	58.8%-7.7pp	66.5%-7.6pp	74.2%-5.3pp	79.4%+2.1pp	77.3%-2.8pp	80.1%-3.5pp	83.7%-0.9pp	84.6%
Operating Margin	13.5%+23.9pp	-10.4%+58.8pp	-69.2%-54.0pp	-15.2%-34.5pp	19.3%-8.6pp	27.8%+17.5pp	10.3%-1.2pp	11.5%-10.7pp	22.2%+0.6pp	21.6%-5.5pp	27.1%+7.3pp	19.8%+6.1pp	13.7%+3.1pp	10.6%-1.1pp	11.7%
Net Margin	7.1%+25.3pp	-18.3%+54.2pp	-72.5%-53.5pp	-18.9%-31.3pp	12.4%-7.0pp	19.4%+14.5pp	4.9%-3.1pp	8.0%-6.7pp	14.7%+4.1pp	10.6%-1.4pp	12.0%+3.9pp	8.2%-1.8pp	10.0%+1.6pp	8.3%-0.1pp	8.4%
Return on Equity	10.1%+49.5pp	-39.5%+77.6pp	-117.1%-101.9pp	-15.3%-28.9pp	13.6%-7.5pp	21.1%+16.1pp	5.0%-1.2pp	6.2%-2.8pp	9.0%+0.4pp	8.7%-0.8pp	9.5%+2.9pp	6.6%+0.3pp	6.4%+1.0pp	5.3%-0.2pp	5.6%
Return on Assets	4.0%+17.7pp	-13.7%+28.0pp	-41.7%-35.0pp	-6.7%-14.1pp	7.4%-3.2pp	10.6%+8.3pp	2.3%-0.5pp	2.8%-4.9pp	7.7%+2.4pp	5.3%-0.7pp	6.1%+2.1pp	3.9%-1.1pp	5.0%+0.8pp	4.2%0.0pp	4.2%
Current Ratio	5.01+1.3x	3.69+2.6x	1.04+0.1x	0.98-2.4x	3.40+0.3x	3.11-0.1x	3.17+0.1x	3.10-1.8x	4.850.0x	4.82-0.6x	5.40+0.7x	4.65-0.2x	4.82+0.6x	4.25+0.7x	3.58
Debt-to-Equity	1.09-0.3x	1.37+0.7x	0.69+0.4x	0.32-0.2x	0.50-0.1x	0.58-0.2x	0.730.0x	0.78+0.8x	0.01-0.4x	0.420.0x	0.37-0.1x	0.45+0.3x	0.130.0x	0.130.0x	0.13
Asset Turnover	0.56-0.2x	0.75+0.2x	0.58+0.2x	0.35-0.2x	0.60+0.1x	0.55+0.1x	0.48+0.1x	0.35-0.2x	0.520.0x	0.500.0x	0.500.0x	0.480.0x	0.500.0x	0.500.0x	0.50
FCF Margin	21.1%+17.7pp	3.4%+28.0pp	-24.6%-11.2pp	-13.4%-18.8pp	5.4%-19.6pp	25.0%+15.9pp	9.1%+13.0pp	-3.9%-31.2pp	27.3%+31.8pp	-4.4%-4.0pp	-0.4%-18.6pp	18.1%+0.6pp	17.6%+22.6pp	-5.0%+10.3pp	-15.3%

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Gross Margin	58.6%+6.0pp	53.9%-6.3pp	42.9%-9.1pp	62.8%+8.0pp	52.5%+71.4pp	60.2%+11.0pp	52.0%+21.4pp	54.9%+22.6pp
Operating Margin	-53.4%-54.5pp	6.7%-15.7pp	-18.8%-13.9pp	33.1%+11.2pp	1.1%+81.0pp	22.5%+9.2pp	-4.9%+11.0pp	21.9%+111.5pp
Net Margin	-76.9%-68.4pp	4.4%-26.2pp	-36.7%-20.6pp	22.1%-16.9pp	-8.5%	30.6%+27.6pp	-16.1%+1.8pp	39.1%+136.5pp
Return on Equity	-52.8%-50.5pp	1.3%-11.0pp	-10.4%-4.0pp	8.8%-13.8pp	-2.2%+71.0pp	12.3%+10.9pp	-6.5%+1.1pp	22.6%+60.4pp
Return on Assets	-16.1%-15.3pp	0.5%-4.3pp	-4.1%-1.9pp	3.5%-4.3pp	-0.9%+17.8pp	4.8%+4.3pp	-2.3%+0.5pp	7.8%+21.7pp
Current Ratio	5.42-0.2x	4.29-2.0x	5.01+1.3x	5.76+2.9x	5.66+4.6x	6.32+5.2x	3.69+2.6x	2.88+1.8x
Debt-to-Equity	1.70+0.5x	1.10-0.1x	1.09-0.3x	1.14-0.2x	1.25+0.1x	1.20+0.5x	1.37+0.7x	1.30+0.7x
Asset Turnover	0.21+0.1x	0.120.0x	0.110.0x	0.160.0x	0.10-0.1x	0.160.0x	0.140.0x	0.20+0.1x
FCF Margin	23.1%-50.4pp	-23.2%-16.5pp	49.6%+91.5pp	-2.5%-52.8pp	73.5%+56.6pp	-6.7%+17.8pp	-41.9%-49.4pp	50.3%+32.8pp

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
Emergent Biosolutions, Inc. EBS	FY2025	$742.9M	$52.6M	7.1%	$362.0M	36/100
Kamada Ltd KMDA	FY2025	$180.5M	$20.2M	11.2%	$448.7M	41/100
Evolus, Inc. EOLS	FY2025	$297.2M	-$51.6M	-17.4%	$515.2M	34/100
SIGA Technologies, Inc. SIGA	FY2025	$94.6M	$23.3M	24.6%	$235.7M	59/100
Eton Pharmaceutcials, Inc. ETON	FY2025	$80.0M	-$4.6M	-5.8%	$1.6B	51/100
Canopy Growth Corporation CGC	FY2026	N/A	-$189.0M	N/A	$358.2M	—

Where Emergent Biosolutions, Inc. Ranks

Frequently Asked Questions

What is Emergent Biosolutions, Inc.'s annual revenue?

Emergent Biosolutions, Inc. (EBS) reported $742.9M in total revenue for fiscal year 2025. This represents a -28.8% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Emergent Biosolutions, Inc.'s revenue growing?

Emergent Biosolutions, Inc. (EBS) revenue declined by 28.8% year-over-year, from $1.0B to $742.9M in fiscal year 2025.

Is Emergent Biosolutions, Inc. profitable?

Yes, Emergent Biosolutions, Inc. (EBS) reported a net income of $52.6M in fiscal year 2025, with a net profit margin of 7.1%.

What is Emergent Biosolutions, Inc.'s EBITDA?

Emergent Biosolutions, Inc. (EBS) had EBITDA of $195.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Emergent Biosolutions, Inc. have?

As of fiscal year 2025, Emergent Biosolutions, Inc. (EBS) had $205.4M in cash and equivalents against $572.1M in long-term debt.

What is Emergent Biosolutions, Inc.'s gross margin?

Emergent Biosolutions, Inc. (EBS) had a gross margin of 56.1% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Emergent Biosolutions, Inc.'s operating margin?

Emergent Biosolutions, Inc. (EBS) had an operating margin of 13.5% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Emergent Biosolutions, Inc.'s net profit margin?

Emergent Biosolutions, Inc. (EBS) had a net profit margin of 7.1% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Emergent Biosolutions, Inc.'s return on equity (ROE)?

Emergent Biosolutions, Inc. (EBS) has a return on equity of 10.1% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Emergent Biosolutions, Inc.'s free cash flow?

Emergent Biosolutions, Inc. (EBS) generated $156.8M in free cash flow during fiscal year 2025. This represents a 338.0% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Emergent Biosolutions, Inc.'s operating cash flow?

Emergent Biosolutions, Inc. (EBS) generated $170.6M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Emergent Biosolutions, Inc.'s total assets?

Emergent Biosolutions, Inc. (EBS) had $1.3B in total assets as of fiscal year 2025, including both current and long-term assets.

What are Emergent Biosolutions, Inc.'s capital expenditures?

Emergent Biosolutions, Inc. (EBS) invested $13.8M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Emergent Biosolutions, Inc. spend on research and development?

Emergent Biosolutions, Inc. (EBS) invested $53.2M in research and development during fiscal year 2025.

Does Emergent Biosolutions, Inc. buy back shares?

Yes, Emergent Biosolutions, Inc. (EBS) spent $24.9M on share buybacks during fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

How many shares does Emergent Biosolutions, Inc. have outstanding?

Emergent Biosolutions, Inc. (EBS) had 52M shares outstanding as of fiscal year 2025.

What is Emergent Biosolutions, Inc.'s current ratio?

Emergent Biosolutions, Inc. (EBS) had a current ratio of 5.01 as of fiscal year 2025, which is generally considered healthy.

What is Emergent Biosolutions, Inc.'s debt-to-equity ratio?

Emergent Biosolutions, Inc. (EBS) had a debt-to-equity ratio of 1.09 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Emergent Biosolutions, Inc.'s return on assets (ROA)?

Emergent Biosolutions, Inc. (EBS) had a return on assets of 4.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Emergent Biosolutions, Inc.'s P/E ratio?

Emergent Biosolutions, Inc. (EBS) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to June 30, 2026). The market capitalization is $362.0M as of Oct 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Emergent Biosolutions, Inc.'s price-to-sales ratio?

Emergent Biosolutions, Inc. (EBS) trades at 0.5x sales, its market capitalization divided by revenue of $770.2M revenue, trailing 12 months to June 30, 2026. The market capitalization is $362.0M as of Oct 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Emergent Biosolutions, Inc.'s Altman Z-Score?

Emergent Biosolutions, Inc. (EBS) has an Altman Z-Score of 1.40, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Emergent Biosolutions, Inc.'s Piotroski F-Score?

Emergent Biosolutions, Inc. (EBS) has a Piotroski F-Score of 8 out of 9, indicating strong financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Emergent Biosolutions, Inc.'s earnings high quality?

Emergent Biosolutions, Inc. (EBS) has an earnings quality ratio of 3.24x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Emergent Biosolutions, Inc. cover its interest payments?

Emergent Biosolutions, Inc. (EBS) has an interest coverage ratio of 1.69x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Emergent Biosolutions, Inc.?

Emergent Biosolutions, Inc. (EBS) scores 36 out of 100 on our Financial Health Score, indicating weak standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.